Articles tagged with Metastasis
A new animal study suggests that exposure to dim light at night may contribute to the spread of breast cancer to bones. Researchers created a mouse model of bone metastatic breast cancer and found that mice exposed to a light/dim light cycle had larger tumors and increased bone damage compared to those in a standard light/dark cycle.
A new study suggests that consuming thermally abused cooking oil may trigger genetic changes that promote the progression of late-stage breast cancer. Mice fed thermally abused oil developed more tumors and aggressive growth than those fed fresh soybean oil, highlighting a potential link between diet and cancer recurrence.
Researchers identified a common oncogene, KRAS, as a key player in immune checkpoint blockade therapy resistance in metastatic colorectal cancer. Restoring IRF2 expression or inhibiting MDSCs through CXCL3-CXCR2 signaling increased CRC sensitivity to ICB therapy.
The NRG-RTOG 0214 trial found that prophylactic cranial irradiation improved disease-free survival, decreased brain metastasis rates, but did not improve overall survival in patients with locally advanced non-small cell lung cancer. This suggests PCI may prolong OS in a subgroup without primary tumor surgery.
Breast cancer researchers found that stress hormones increase glucocorticoid receptor activity in metastatic cells, leading to tumor heterogeneity and reduced chemotherapy effectiveness. Synthetic derivatives of stress hormones also decrease chemotherapy efficacy.
A recent study has found that Focal Adhesion Kinase (FAK) acts as a sensor to mechanical forces generated by the cytoskeleton, activating biochemical signals regulating cell migration. This discovery provides new insights into how cancer cells invade and metastasize, potentially leading to therapies targeting this mechanism.
PET/CT scans can monitor immunotherapy treatment for metastatic melanoma and predict outcome, allowing personalized therapy adjustments. The study demonstrates that FDG PET/CT can accurately assess tumor response to checkpoint inhibitor therapy with ipilimumab.
A new study by Prof. Sarah-Maria Fendt and her PhD student Ilaria Elia found that breast cancer cells require pyruvate to reshape the lung environment and create a pro-tumor niche. In contrast, normal bone cells rely on glutamine for this process.
Researchers found that estrogen affects astrocytes, which produce growth factors promoting brain metastasis. Anti-estrogen therapy may prevent brain metastasis in women with triple-negative breast cancer.
Researchers at Ben-Gurion University and Texas Southwestern Medical Center developed AI-powered technology to identify melanoma cells with metastatic potential. The technology uses quantitative live cell histology to record video of cells and analyze their appearance and behavioral patterns.
Ralf Janknecht's research on the molecule DNPH1, overproduced in breast cancer, suggests it could serve as a new drug target for reducing cancer metastasis. The removal of DNPH1 from mouse models resulted in fewer tumors and a tenfold reduction in metastasis.
A new reversible antiplatelet therapy has been developed to reduce blood clots and prevent cancer metastasis. The therapy uses decoy platelets that can bind to cancer cells without activating the normal clotting process, offering a promising new approach to treating diseases.
Researchers developed a reversible antiplatelet therapy using deactivated platelets that can reduce the risk of blood clots and prevent cancer metastasis. By adding fresh platelets, the inhibition of normal platelet activity is rapidly reversed, allowing patients to quickly regain their ability to form blood clots.
Researchers created platelet decoys that prevent blood clots and combat cancer spread, offering a promising new therapy. The fast-reversible approach could one day treat life-threatening bleeding in emergencies or surgical settings.
Researchers discovered that cancer cells growing in lymph nodes prefer to use fatty acids rather than glucose as an energy source. The metabolic adaptation was found to be triggered by the activation of yes-associated protein (YAP), which stimulates fatty acid oxidation in metastatic tumor cells.
Researchers at the University of Basel found that neutrophils help tumor cells form metastases by escorting circulating tumor cells. This alliance enhances their ability to seed metastasis, and blocking it could lead to new anti-metastatic drugs.
Patients treated at minority-serving hospitals have only about two-thirds the odds of receiving palliative care compared to those receiving care at typical hospitals. The study found that racial and ethnic minorities are less likely to receive end-of-life palliative care than their counterparts, regardless of race or ethnicity.
Researchers found a causal connection between MDMX overexpression and triple-negative breast cancer metastasis. The study suggests targeting the MDMX protein could prevent cancer spread, offering potential for new treatments.
Research finds that plerixafor reduces fibrosis and improves response to immunotherapy in mouse models of metastatic breast cancer. Fibrosis blocks effectiveness of immunotherapies, but CXCR4 inhibition enhances immune cell infiltration and decreases formation of spontaneous metastases.
Researchers found that cancer cells switch to brute force and build a protrusion when MMP enzymes aren't available. This allows them to penetrate the basement membrane and invade other organs. The study identified a mitochondrial gene target that could be used to develop new treatments.
Jun Ho Lee, a doctoral student at UNIST, received the grand prize of $10,000 from Merck's 2018 Life Science Awards in Tumor Biology. His research on TonEBP expression in hepatocellular carcinoma has shown promise in predicting patient prognosis and preventing cancer recurrence.
A new PET probe targets melanin pigment in skin cancer lesions to improve detection of primary and metastatic melanoma. The probe shows promising results in clinical trials, outperforming existing methods like 18F-FDG PET/CT scans.
A study found that breast cancers diagnosed in young women within 10 years of giving birth are more likely to metastasize than those diagnosed less recently or not at all. The risk is highest among women up to 10 years postpartum and is most pronounced in stage I or II breast cancer.
A dual COX-2/sEH inhibitor may offer a novel alternative to protect against debris-mediated inflammatory responses, which can lead to tumor survival and growth. The study used mouse models of ovarian cancer to demonstrate the anti-inflammatory compound's effectiveness in suppressing cancer growth.
Researchers at the University of Basel have developed a novel differentiation therapy that converts breast cancer cells into fat cells, impeding the formation of metastases in mice. The therapy combines two active substances, Rosiglitazone and Trametinib, to suppress tumor growth and spread.
Researchers have discovered molecular mechanisms that enable the transmission of a deadly facial tumor among Tasmanian devils. The study found that ERBB receptors and STAT3 proteins play a key role in the transmissibility of the disease, which has killed 90% of the wild population.
Researchers successfully converted invasive breast cancer cells in mice into harmless fat cells using two FDA-approved drugs, suppressing tumor growth and metastasis. This breakthrough could potentially deplete a tumor's ability to fight off conventional chemotherapy.
Basel researchers identified a substance that prevents the formation of metastases by dissociating circulating tumor cell clusters and reversing epigenetic changes. This approach targets key aspects of metastasis seeding, including proliferation and tissue-forming capabilities.
Researchers discover a potential therapy that can disrupt the recruitment of myeloid cells by cancerous tumors, boosting the function of disease-fighting M1 type of myeloid cells. This approach shows great promise in reducing tumor growth and promoting a microenvironment where T cells can attack cancer.
Researchers at Thomas Jefferson University discovered a compound from Christmas berry primrose plants can inhibit uveal melanoma growth, offering potential new treatments for patients. The compound, FR900359, works by blocking mutated G proteins that promote cancer growth.
A comprehensive study reveals that p62 protein controls multiple factors involved in melanoma metastasis, indicating a coordinated process. The research also identifies FERMT2 as a marker for poor patient prognosis.
Researchers discovered that ovarian cancer cells colonize the omentum after being caught in DNA 'webs' extruded by immune cells. Inhibiting NET formation reduces metastasis in mice, suggesting a new approach to limit ovarian cancer spread. This study provides insights into improving ovarian cancer treatment.
A new assay can analyze small amounts of material to estimate metastatic risk, enhancing prostate cancer evaluation. The Next-Generation Copy Number Alteration (NG-CNA) assay is a targeted amplification sequencing technique that can process samples faster and decrease the cost per sample.
A multigene test used in breast cancer treatment helps doctors decide on chemotherapy, improving prognosis and reducing unnecessary treatments. The study found that patients with high-risk tumors had a five-fold increased risk of metastases and lower disease-free survival rates without chemotherapy.
Researchers have engineered sensors to monitor multiple signaling pathways driving tumor metastasis, enabling the prediction of a tumor cell's potential to spread. The development of Fluorescence Resonance Energy Transfer (FRET) biosensors has the potential to transform cancer cell biology and inform personalized treatment strategies.
Researchers at the University of Tokyo have discovered that blocking a specific molecule can prevent cancer cells from spreading. The study found that inhibiting tissue type plasminogen activator (tPA) blocked melanoma growth and metastasis in mice. This breakthrough offers new possibilities for cancer therapy, potentially improving ou...
Researchers have found a potential Achilles' heel in micrometastasis that could be targeted with medications to reduce the risk of full-blown metastasis. Blocking calcium transfer through gap junctions and mTOR pathway results in cancer cell death or growth inhibition.
Researchers have discovered that metastatic cancer cells follow a Lévy walk movement pattern, like sharks searching for food, which aids in their rapid spread and direction. The team was able to reprogram this behavior using chemical inhibitors, changing it back to more typical diffusive motion
A recent study published in the British Journal of Cancer found a positive association between type 2 diabetes and an increased risk of colorectal cancer (CRC) in men, with a moderately higher risk observed. In contrast, the association was weaker and not statistically significant for women. The study followed up over 87,000 women and ...
Breast cancer cells can become invasive by changing their identity through a process called epithelial-mesenchymal transition (EMT). A newly identified protein, CXADR, plays a crucial role in this process. Reintroducing CXADR into breast cancer cells can change their behavior and repress invasive properties.
Researchers at CNIO have linked the protein MASTL to a type of inherited thrombocytopenia, which may lead to breakthroughs in cancer metastasis research. They discovered that manipulating other enzymes could potentially reverse the defect and explored its therapeutic potential.
The NRG Oncology clinical trial BR001 found that SBRT is safe for patients with 2 metastases or 3-4 metastases in specific locations, including peripheral lung and abdomen/pelvic. The study showed zero protocol-defined dose-limiting toxicities across evaluable anatomic locations.
A randomized phase III trial found that avoiding the hippocampal region during whole-brain radiotherapy significantly reduces the risk of cognitive decline. The study results have far-reaching implications for brain tumor treatment, offering a safer alternative to traditional whole-brain radiation therapy.
A new immunotherapy combination shows durable clinical benefits in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer, with 60% objective response rate and 84% of patients experiencing tumour shrinkage. The treatment is also well-tolerated, with manageable side effects.
A large comparison study found that radiotherapy to the prostate improved failure-free survival but not overall survival in men with newly diagnosed metastatic prostate cancer and a low burden of disease. The treatment was well-tolerated, with only modest side effects.
A large study found that drugs approved for women's breast cancer are also effective and well-tolerated in men. Men with metastatic breast cancer received similar treatments to women, including hormonal therapy and chemotherapy, with similar outcomes.
Atezolizumab, an antibody targeting PD-L1, improved survival in metastatic triple negative breast cancer patients by 20%, particularly those with PD-L1 positive tumors. The combination therapy also reduced disease worsening and death risk by 38% in PD-L1 positive subgroup
A new statistical method estimates the short- and long-term risk of recurrence for hormone receptor-positive and HR-negative breast cancers in US women. The study found that while HR-positive breast cancer has a lower risk of progression to metastatic disease soon after diagnosis, the risk persists for several years.
Neutrophils isolated from bone marrow of mouse models and patients with early stage tumors exhibit increased spontaneous migration to tissues and promote tumor cell seeding. These neutrophils lack immunosuppressive characteristics, but display potent ability to spontaneously migrate and facilitate metastasis.
Researchers at Mount Sinai have discovered a new way to determine whether breast cancer cells are dormant or soon to turn deadly. Patients with high levels of the NR2F1 protein in their bone marrow are less likely to develop metastatic cancer, allowing for more targeted treatment and improved survival rates.
A new report reveals a protein, deltaNp63, that directs myeloid-derived immunosuppressor cells (MDSCs) to the primary tumor and metastatic sites, promoting tumor growth and metastasis. Blocking deltaNp63 or MDSCs reduced tumor growth and metastasis in a mouse model of triple-negative breast cancer.
Patients with metastatic non-small cell lung cancer (NSCLC) treated at academic centers had higher 2-year survival rates than those treated at community-based centers. The study found significant differences in survival outcomes based on facility type, histology, and molecular profile.
A new study suggests targeting collagen XIII could suppress breast cancer metastasis by enhancing anoikis resistance in cancer cells. Researchers found that collagen XIII expression is significantly higher in cancerous human breast tissue and necessary for metastasis in mouse models.
Researchers at Cold Spring Harbor Laboratory found that sustained lung inflammation can awaken dormant breast and prostate cancer cells, leading to metastasis. A new antibody approach may block this signaling pathway, preventing cancer recurrence.
Researchers at UC Riverside have discovered a way to target migrating cancer cells, responsible for tumor metastases, using novel agents 135H11 and 135H12. These potent agents can block EphA2, an oncogene that spreads cancer, preventing cell migration and degradation.
Researchers discovered that driver gene mutations are remarkably similar across different metastases from the same patient, offering hope for successful targeted therapies. This finding suggests that single biopsies can capture essential information for therapeutic decision-making.
Phase 1 and phase 2 clinical trials of entrectinib in ROS1-positive non-small cell lung cancer demonstrated a response rate of 77.4 percent and median duration of response of 24.6 months. Entrectinib also showed competitive results in patients with brain metastases and poor prognosis
Scientists at the Medical University of South Carolina discovered that over-expression of VRK1 actually slows down cancer cell migration and invasion, but enables cells to form colonies under 3D conditions. High levels of VRK1 are associated with aggressive breast cancers and poor prognoses in patients with metastatic breast cancer.
Researchers at UCLA have created a quick and effective mechanism to measure how circulating tumor cells perform functions that drive disease, such as producing proteins that degrade tissue. The new approach enables scientists to understand how tumor cells act, rather than just what they are made from.
A new study identified 'signposts' on cancer cells that can help the immune system recognize and kill them, potentially leading to higher recovery rates. The findings suggest a highly personalized approach to immunotherapy could improve treatment outcomes.